- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01517984
Immunövervakning och CNI-abstinens hos lågriskmottagare av njurtransplantation
Immunövervakning och uttag av kalcineurinhämmare (CNI) hos lågriskmottagare av njurtransplantation
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90055
- University of California Los Angeles
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06520-8029
- Yale University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Hospital
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Mount Sinai School of Medicine
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Förenta staterna, 44106-5048
- University Hospitals of Cleveland
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- The Methodist Hospital
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3A IR9
- Health Sciences Centre
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M1
- Toronto General Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
INCLUSION CRITERIA -
Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:
- Subject must be able to understand and provide written informed consent;
- Primary living-donor (related or unrelated) kidney transplant recipients;
- Peak flow-based PRAs for class I and class II <30%(performed by local center);
- Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
- No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
- Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
- Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
- Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.
Inclusion Criteria for Randomization:
Participants who meet all of the following criteria are eligible for randomization:
- No history of acute rejection episodes;
- The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
- No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).
EXCLUSION CRITERIA -
Initial Enrollment/Screening:
Participants who meet any of these criteria are not eligible for enrollment as study subjects:
- Recipient of multiple organ transplants;
- Prior history of organ transplantation;
- Deceased-donor source;
- Any condition that would preclude protocol biopsies;
- HLA identical recipients;
- Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
- Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
- Inability or unwillingness to comply with study protocol;
- Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.
Exclusion Criteria for Randomization:
Participants who meet any of these criteria are not eligible for randomization:
- Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
- Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
- Any condition that would preclude protocol biopsies;
- Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
- Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
- Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
- Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
- Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Tacrolimus (CNI) Withdrawal
Subjects randomized (2:1) to tacrolimus (CNI) withdrawal. Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal. |
Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.
Andra namn:
Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Andra namn:
|
|
Aktiv komparator: Standard Immunosuppressive Therapy
Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal. Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur. |
Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization
Tidsram: IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.
|
The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules. |
IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation
Tidsram: 6 months post-transplantation, 24 months post-transplantation
|
Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function |
6 months post-transplantation, 24 months post-transplantation
|
|
Incidence of Acute Rejection
Tidsram: 6 to 18 months post-randomization
|
Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events. |
6 to 18 months post-randomization
|
|
Allograft Survival Rate
Tidsram: 6 to 18 months post-randomization
|
Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study. |
6 to 18 months post-randomization
|
|
Participant Survival Rate
Tidsram: 6 to 18 months post-transplantation
|
Number of participants who did not die within the course of this study. |
6 to 18 months post-transplantation
|
|
Percentage of Participants With New Donor Specific Antibodies (DSAs)
Tidsram: 6 to 18 months post-randomization
|
Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection. |
6 to 18 months post-randomization
|
|
Percentage of Participants With Donor-Specific Memory Using Elispot
Tidsram: 6 to 18 months post-randomization
|
This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met. |
6 to 18 months post-randomization
|
|
Percentage of Participants in the Experimental Arm Off Tacrolimus
Tidsram: 18 months post-randomization
|
Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies. |
18 months post-randomization
|
|
Incremental Change in IF/TA Scores
Tidsram: 6 to 18 months post-transplant
|
This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met. |
6 to 18 months post-transplant
|
|
Measurement of Urinary Parameters Before and After Randomization
Tidsram: 6 months post-transplantation to 18 months post-randomization
|
This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met. |
6 months post-transplantation to 18 months post-randomization
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Donald Hricik, MD, University Hospitals Cleveland Medical Center
- Huvudutredare: Peter S. Heeger, MD, Icahn School of Medicine at Mount Sinai
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Organiska kemikalier
- Fettsyror
- Lipider
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Syror, acykliska
- Karboxylsyror
- Polycykliska föreningar
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Makrolider
- Laktoner
- Gravidioder
- Caproates
- Prednison
- Mykofenolsyra
- Takrolimus
- Calcineurin-hämmare
- tymoglobulin
- cni-protein, Drosophila
Andra studie-ID-nummer
- DAIT CTOT-09
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .